Despite the fact that several experimental evidence link for example ERK1/2 activation in glioma cells with c-FLIP [348] or JNK activation with RIPK1 [363], it remains unclear how upstream kinases are integrated and activated in the molecular platforms triggered by TRAIL, whether it be complex I or complex II. The gene discussed is MAPK3; the disease is glioma.